EUVIMEDEUVIMED entdecken
Crossref

Improving patient selection through tumor genomic recharacterization to overcome resistance to targeted therapy: commentary on the final analysis of the INSIGHT trial

Federica Pecci, Biagio Ricciuti, Joao V. Alessi, Andrea De Giglio, Alessandro Di Federico

AME Clinical Trials Review · 2023

DOI: 10.21037/actr-23-29 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AME Clinical Trials Review, 2023. Verfasst von Federica Pecci und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Pecci, F., Ricciuti, B., Alessi, J. V., Giglio, A. D., & Federico, A. D. (2023). Improving patient selection through tumor genomic recharacterization to overcome resistance to targeted therapy: commentary on the final analysis of the INSIGHT trial. AME Clinical Trials Review. https://doi.org/10.21037/actr-23-29

Vancouver

Pecci F, Ricciuti B, Alessi JV, Giglio AD, Federico AD. Improving patient selection through tumor genomic recharacterization to overcome resistance to targeted therapy: commentary on the final analysis of the INSIGHT trial. AME Clinical Trials Review. 2023. doi:10.21037/actr-23-29

BibTeX
@article{Pecci2023,
  author = {Pecci, Federica and Ricciuti, Biagio and Alessi, Joao V. and Giglio, Andrea De and Federico, Alessandro Di},
  title = {Improving patient selection through tumor genomic recharacterization to overcome resistance to targeted therapy: commentary on the final analysis of the INSIGHT trial},
  journal = {AME Clinical Trials Review},
  year = {2023},
  doi = {10.21037/actr-23-29}
}
Kostenlos starten →